跳至主要内容
临床试验/DRKS00025893
DRKS00025893招募中不适用

A multicenter, prospective cohort study to document the immunization status of MS patients in Germany with focus on anti-SARS-CoV-2 vaccination response (COVID-19) - SARS-CoV-2-related MS Vaccination Study

Biogen GmbH0 个研究点目标入组 200 人开始时间: 2021年7月15日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
Biogen GmbH
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1. Male or female patients of at least 18 years of age at time of informed consent
  • 2. Diagnosis of MS according to McDonald criteria (2018)
  • 3. Ability to understand the purpose of the study and provide signed and dated study-specific informed consent form (ICF)
  • 4. SARS-CoV-2 vaccination is planned (within the upcoming 90 days), underway (only one of two vaccinations received) or only recently completed (in the last 6 weeks).
  • SARS-CoV-2 vaccination has been completed > 6 weeks but an additional vaccination is planned within the upcoming 90 days.
  • 5. In case of prior SARS-CoV-2 infection(s), patient has recovered from infection.

排除标准

  • 1. Patient cannot be regularly followed up for organizational or geographic reasons.
  • 2. Patient is unwilling to get vaccinated against SARS COV-2 virus.

研究者

发起方
Biogen GmbH

相似试验

A multicenter, prospective cohort study to document... | 临床试验